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Abstract: Antimicrobial stewardship has become standard practice at university medical 
centers, but the practice is more difficult to implement in remote community hospitals that 
lack infectious diseases trained practitioners. Starting in 2011, six community hospitals 
within the Vidant Health system began an antimicrobial stewardship program utilizing 
pharmacists who reviewed charts remotely from Vidant Medical Center. Pharmacists made 
recommendations within the electronic medical record (EMR) to streamline, discontinue, 
or switch antimicrobial agents. Totals of charts reviewed, recommendations made, 
recommendations accepted, and categories of intervention were recorded. Linear regression 
was utilized to measure changes in antimicrobial use over time. For the four larger hospitals, 
recommendations for changes were made in an average of 45 charts per month per hospital 
and physician acceptance of the pharmacists’ recommendations varied between 83% and 
88%. There was no significant decrease in total antimicrobial use, but much of the use was 
outside of the stewardship program’s review. Quinolone use decreased by more than 50% 
in two of the four larger hospitals. Remote antimicrobial stewardship utilizing an EMR is 
feasible in community hospitals and is generally received favorably by physicians.  
As more community hospitals adopt EMRs, there is an opportunity to expand antimicrobial 
stewardship beyond the academic medical center. 








The overuse and misuse of antimicrobial agents is a global problem that has led to the development 
of antimicrobial resistance in both the hospital and community setting. One of the primary strategies 
for combating resistance is through the use of antimicrobial stewardship programs (ASPs) [1,2].  
The ASP’s primary goal includes optimizing antimicrobial use through reduction of unnecessary 
antimicrobial use and confirmation of proper antimicrobial use (including drug, dose, route, and 
duration), in order to achieve the best clinical outcomes. While ASPs have been proven effective in 
both academic hospitals [3] and smaller community hospitals [4], small community hospitals tend to 
have more difficulty establishing these programs. These difficulties include staffing constraints, lack of 
funding, and lack of administrative and medical staff support [5]. 
Vidant Medical Center (VMC) has had a successful ASP in place since 2001. The ASP uses  
a primary strategy of prospective audit with feedback. Given the success of the ASP at the tertiary care 
center, we expanded the ASP to six of the seven community hospitals within the Vidant Health (VH) 
system. In December 2011 the ASP was implemented at Vidant Roanoke-Chowan Hospital (VROA), 
in March 2012 at Vidant Bertie Hospital (VBER), Vidant Chowan Hospital (VCHO), and The Outer 
Banks Hospital (OBH), in October 2013 at Vidant Duplin Hospital (VDUP), and in December 2013 at 
Vidant Beaufort Hospital (VBEA). We were able to accomplish this process through use of the 
electronic medical record (EMR) Epic (Madison, WI, USA), which is shared across the VH system [6]. 
To date, we are unable to locate any previous attempt at managing an ASP via EMR and central 
monitoring. We currently collect data on intervention outcomes, cost savings, physician acceptance 
rates, number of charts reviewed, number of recommendations made, anti-methicillin-resistant 
Staphylococcus aureus (MRSA) drug use, anti-pseudomonal drug use, broad spectrum drug use, and 
total antimicrobial drug use. 
2. Methods 
2.1. Central ASP at VMC 
VMC is a 909-bed, tertiary-care academic medical center affiliated with the Brody School of 
Medicine at East Carolina University (Greenville, NC, USA). VMC’s ASP was established in 2001 
and has been reviewed in previous publications [7,8]. This ASP was formed by the Antimicrobial 
Utilization & Stewardship Subcommittee (AUSS) and was approved by the Pharmacy and 
Therapeutics Committee and the medical staff executive committee. When the ASP first started it had 
an infectious diseases physician director and one pharmacist (1 full time equivalent [FTE]), with  
an additional pharmacist added in 2004 (0.5 FTE) and two additional pharmacists added when the 
program expanded to the community hospitals (1.5 FTE). All members of the ASP are physically 
located at VMC. The VH ASP fully operates five days per week with on-call and follow-up services 
provided on the weekend. Patient chart review for VMC is completed by one of the pharmacists for all 
adult patients that have been on a restricted or controlled antibiotic for ≥72 h. 
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2.2. Expansion of the ASP to Vidant Community Hospitals 
VMC is the flagship hospital of the VH system. Including VMC, VH currently has eight hospital 
locations across eastern North Carolina with six of seven community hospitals being a part of this 
ASP. These six community hospitals are described in Table 1. None of the community hospitals within 
this ASP have infectious diseases consult services. While some of these hospitals do have a few order 
sets that were in place prior to the ASP, there are no formal infection related guidelines at any of these 
hospitals. To initiate implementation of an ASP at each community hospital, the physician director and 
pharmacist representative(s) visited each hospital to describe the program, discuss specifics, and begin 
to build relationships with the local physicians, pharmacists, infection control practitioners, and 
microbiology staff. 
Table 1. Characteristics of Vidant community hospitals. 
Hospital Name Beds ASP Start Date Services 
Vidant Beaufort Hospital, 
Washington, NC (Hospital A) 
142 December 2013 
medical, surgical, intensive care, emergency, 
and orthopedics 
Vidant Chowan Hospital, Edenton, 
NC (Hospital B) 
49 March 2012 
medical, surgical, intensive care, emergency, 
and orthopedics 
Vidant Duplin Hospital, 
Kenansville, NC (Hospital C) 
81 October 2013 
medical, surgical, intensive care, emergency, 
and orthopedics 
Vidant Roanoke-Chowan Hospital, 
Ahoskie, NC (Hospital D) 
114 December 2011 
medical, surgical, intensive care, emergency, 
orthopedics, and wound care 
Vidant Bertie Hospital, Windsor, 
NC (Hospital E) 
6 March 2012 medical and emergency 
The Outer Banks Hospital,  
Nags Head, NC (Hospital F) 
21 March 2012 medical, surgical, emergency, and orthopedics 
At these hospitals, any adult patient that receives a controlled antimicrobial for ≥24 h triggers  
a chart review by the ASP pharmacist and is listed on the EMR-generated report that is run daily 
Monday through Friday. A full list of all controlled antimicrobials can be found in Table 2. The 
formulary restriction program in place at VMC is not currently in place at the community hospitals. 
The time window for antibiotic use that triggered a chart review was shortened from 72 h to 24 h at the 
community hospitals after it was noticed that the length of stay at the community hospitals was 
generally shorter than it is at VMC. Based on microbiology culture results, radiology reports, and the 
working diagnosis, the pharmacist, with input from the physician director, makes recommendations to 
change or stop the controlled antimicrobial agent(s) by leaving a note in the EMR. These 
recommendations are generally based off of the guidelines published by the Infectious Diseases 
Society of America (IDSA). After a note is left, the physician can make the recommended change(s) 
on his/her own or reply in a progress note or as an addendum to the ASP note with the reason why 
current therapy will continue. After 24 h, if the recommendation is not acknowledged by the primary 
provider then the ASP pharmacist implements the recommendation per protocol as a telephone order 
from the ASP physician director. 
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Table 2. Antimicrobials classified as controlled by the antimicrobial stewardship program 














Colistimethate (or colistin) Tobramycin 
Dalbavancin Vancomycin 
Daptomycin Voriconazole  
Ertapenem Non-formulary antibiotics 
2.3. ASP Data Collection 
Antimicrobial drug use was measured for each hospital for all antimicrobials used in defined daily 
dose per 1000 patient-days (DDD/1000 PD) according to World Health Organization (WHO) 
standards (http://www.whocc.no/atcddd/). This drug usage included anti-fungals, anti-virals, and  
anti-bacterial agents, including drugs that are not considered controlled and that are not evaluated by 
the ASP. Certain antimicrobials are also divided into additional categories. Anti-pseudomonal agents 
included ceftazidime (not on formulary), cefepime, piperacillin/tazobactam, meropenem, doripenem 
(not on formulary), imipenem (not on formulary), ciprofloxacin, levofloxacin (not on formulary), 
aminoglycosides, and aztreonam. Anti-MRSA agents included ceftaroline, clindamycin, daptomycin, 
dalbavancin, doxycycline, linezolid, tedizolid, tigecycline, trimethoprim/sulfamethoxazole, and 
vancomycin. This data was collected by the ASP on a quarterly basis and was used to trend usage  
over time.  
Each recommendation left by the ASP and accepted by the primary provider was then classified 
under one of nine different types of intervention. The intervention types included: additional test 
required to make diagnosis, adverse event avoided, antibiotic-pathogen matched, dose adjusted, 
empiric antibiotic recommendation, drug discontinued, intravenous (IV) to oral (PO) switch,  
de-escalation of therapy, and indwelling urinary catheter discontinued or changed. Each quarter we 
determined how many of the accepted interventions fell into each of these categories. For all of the 
interventions that resulted in a drug being discontinued, we estimated a cost-avoidance for the hospital 
determined by the institutional acquisition cost of the drug and the number of days of therapy spared 
(assuming the initial order continued through completion of a seven day course). Seven days was used 
as the default duration because all antimicrobial orders are automatically given a duration of seven 
days in the EMR. Patients who had drugs discontinued but were then discharged are documented 
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separately. The number of charts reviewed, number of recommendations made (percent intervention), 
and number of recommendations accepted by the primary provider (physician acceptance rate) were 
also collected for each hospital on a monthly basis. 
2.4. Surveillance Definitions 
Nosocomial Gram-negative and Gram-positive data sets were created by querying MedMined® 
(CareFusion, Birmingham, AL, USA). These definitions are the same as those currently used at VMC [6]. 
All clinical care unit specimens (blood, sterile fluid, sputum, urine, wounds and anaerobic specimens) 
taken between 1 July 2010 and 30 June 2015 from hospitals A–F were included. Percent susceptible 
was defined as the percentage of total isolates that were susceptible to the selected antimicrobial. 
Intermediately susceptible isolates were classified as resistant. Susceptibility profiles were compared 
on a year-by-year basis. 
2.5. Epic 
Currently every hospital in the VH system uses Epic. Each hospital’s remote ASP uses the same 
process and reporting as VMC [6]. First, an electronic progress note with the ASP recommendation 
was entered into the EMR. The ASP pharmacist then entered a unique order into the system entitled 
“antimicrobial management”. This order functioned as a best practice alert. Whenever a physician or 
other provider logged into a patient’s chart, the EMR automatically opened a new window with  
a message from the ASP to the provider. This communication window alerted the provider that the 
ASP had left a recommendation in the EMR. The provider then had 24 h to respond to (i.e., accept or 
reject) the recommendation per medical staff guidelines. At this time, the “antimicrobial management” 
order was discontinued. Internally written reports from the Epic reporting manual were used to identify 
patients and collect usage, outcome, and workload data. 
2.6. Statistics 
Statistical analysis was performed using IBM SPSS Statistics versions 22 and 23 (IBM Corp., Armonk, 
NY, USA). Linear regression was used to examine antimicrobial use and antimicrobial susceptibility from 
ASP implementation date through June 2015. A p-value of ≤0.05 was considered significant. 
3. Results 
3.1. Workload and Physician Acceptance 
Total number of charts reviewed, recommendations made, and recommendations accepted are in 
Table 3. The first month for each hospital was omitted due to the beginning of the ASP being in the 
middle of the month. The average number of charts reviewed per month ranged from 17 to 148.  
The percent of recommendations made per charts reviewed per month ranged from 40% to 63%.  
The percent of recommendations accepted per month by the physician ranged from 81% to 95%. 
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Table 3. Monthly antimicrobial stewardship program (ASP) activity (first full month of 
ASP through June 2015). 
Hospital A B C D E F 













Adult inpatient days 14,840 17,134 11,379 41,169 5017 9531 
Total number of charts reviewed 1563 1753 1179 6797 669 943 
Average number of charts reviewed/month 87 45 59 148 17 24 
Average number of recommendations/month 39 25 24 93 9 12 
Average number of recommendations 
accepted/month 
33 20 21 78 8 9 
Recommendations/charts reviewed (%) * 45% 57% 40% 63% 54% 47% 
Recommendations accepted (%) * 83% 85% 88% 87% 95% 81% 
* Based on actual numbers not averages. 
3.2. Intervention Outcomes and Cost Savings 
Classification of outcomes for accepted interventions between January 2014 and June 2015 are in 
Table 4. The recommendations by the ASP most often resulted in antimicrobial drug discontinuation. 
Hospital drug cost savings were also calculated for each drug discontinued using the days of antibiotic 
therapy avoided and multiplying by the institutional acquisition cost of antibiotic therapy per day.  
As mentioned above, seven days was used as the default assumed duration because all antimicrobial 
orders are automatically given a duration of seven days in the EMR. The total cost savings associated 
with the drugs discontinued between January 2014 and June 2015 were as follows: hospital A, 
$16,928; hospital B, $7008; hospital C, $5887; hospital D, $53,618; hospital E, $4309; hospital F, 
$1616. These cost savings reflect only drug cost and do not account for other costs savings which 
include but are not limited to IV supplies, nursing time, pharmacy time, or avoidance of opportunistic 
infections. Patients who were discharged without antimicrobial therapy are documented separately, 
since there is no cost avoidance for the hospital. The number of patients who were discharged without 
antimicrobial therapy between January 2014 and June 2015 were as follows: hospital A, 57 patients; 
hospital B, 35 patients; hospital C, 30 patients; hospital D, 154 patients; hospital E, 14 patients; 
hospital F, 14 patients. 
Table 4. Accepted interventions from January 2014 through June 2015 by hospital. 
Intervention (Number over Past 18 Months) A B C D E F 
Additional Test Required to Make Diagnosis 9 2 2 24 4 2 
Adverse Event Avoided 34 10 21 45 7 9 
Antibiotic-Pathogen Matched 31 20 27 68 5 3 
Dose Adjusted 76 33 51 106 7 10 
Empiric Antibiotic Recommendations 50 48 40 128 15 11 
Drug Discontinued 279 168 132 747 78 50 
IV to PO 100 84 63 345 43 32 
Foley Discontinued or Changed 2 1 2 2 1 0 
De-escalation of therapy 38 17 23 105 7 12 
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Hospital A            ↓        
Quinolones - - - - - - - - 176 157 156 161 155 157 112 178 159 128 N/S 
Cephalosporins - - - - - - - - 205 188 206 204 185 209 238 250 237 291 * 0.003 
Macrolides - - - - - - - - 125 229 194 150 270 100 115 124 99 143 N/S 
Anti-Pseudomonal - - - - - - - - 248 231 267 210 228 239 259 254 201 226 N/S 
Anti-MRSA - - - - - - - - 265 271 249 244 276 342 247 301 233 334 N/S 
Total  - - - - - - - - 1043 1199 1230 1141 1275 1329 1219 1243 1108 1245 N/S 
Hospital B     ↓               
Quinolones - - 378 420 370 354 250 220 114 110 108 161 155 156 141 195 177 161 * 0.001 
Cephalosporins - - 338 410 387 360 384 333 322 372 319 291 399 355 348 374 334 428 N/S 
Macrolides  - - 226 295 265 310 226 275 334 228 236 228 271 208 186 334 301 297 N/S 
Anti-Pseudomonal - - 630 554 470 513 369 361 170 184 166 175 226 199 236 265 205 309 * 0.001 
Anti-MRSA - - 294 267 224 361 276 221 229 307 246 264 296 338 322 252 256 324 N/S 
Total  - - 1750 1772 1623 1918 1492 1378 1334 1405 1259 1281 1526 1465 1436 1640 1513 1671 N/S 
Hospital C            ↓        
Quinolones - - - - - - - 137 131 141 122 182 147 129 133 150 141 128 N/S 
Cephalosporins - - - - - - - 330 318 275 270 323 305 372 426 342 294 331 N/S 
Macrolides - - - - - - - 372 324 305 273 259 280 227 205 259 206 211 * <0.001 
Anti-Pseudomonal - - - - - - - 174 134 213 176 161 175 167 183 183 202 200 N/S 
Anti-MRSA - - - - - - - 306 434 371 366 511 336 399 389 360 282 258 N/S 
Total - - - - - - - 1438 1448 1476 1352 1573 1484 1507 1498 1494 1292 1352 N/S 
Hospital D    ↓                
Quinolones 296 262 287 222 230 188 190 169 138 122 133 179 154 135 119 119 132 101 * <0.001 
Cephalosporins 235 183 217 226 209 291 197 194 214 241 247 290 252 316 330 280 331 393 * <0.001 
Macrolides 163 100 102 120 159 102 106 135 135 113 104 144 199 140 143 166 171 163 * 0.029 
Anti-Pseudomonal 482 470 448 385 317 311 280 280 208 217 212 233 211 256 226 215 244 280 * <0.001 
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Hospital D    ↓                
Anti-MRSA 275 280 306 269 213 300 264 244 235 263 262 375 254 378 271 249 290 252 N/S 
Total 1282 1164 1221 1136 1045 1214 1090 1093 1005 1038 1062 1373 1167 1355 1195 1277 1349 1353 N/S 
Hospital E     ↓               
Quinolones - 624 580 537 584 406 372 250 226 217 168 152 281 237 195 218 251 204 * <0.001 
Cephalosporins - 428 315 410 495 412 443 435 128 467 480 362 391 427 492 681 581 758 * 0.021 
Macrolides - 286 210 393 355 312 215 577 744 302 264 299 492 640 478 790 632 575 * 0.008 
Anti-Pseudomonal - 697 674 609 656 483 428 409 82 220 303 181 199 276 197 255 143 388 * <0.001 
Anti-MRSA - 119 268 256 236 416 243 286 385 257 269 357 231 337 296 339 352 279 N/S 
Total - 1810 1627 1870 2169 1723 1542 1978 1653 1607 1486 1647 1788 2041 1810 2426 2235 2491 N/S 
Hospital F     ↓               
Quinolones - - - - 328 419 # 350 329 362 359 367 356 379 424 262 270 327 N/S 
Cephalosporins - - - - 518 379 # 760 460 520 523 516 494 619 572 533 423 487 N/S 
Macrolides - - - - 215 179 # 394 283 297 430 233 241 362 322 182 260 270 N/S 
Anti-Pseudomonal - - - - 305 431 # 446 242 316 418 273 325 423 516 352 344 402 N/S 
Anti-MRSA - - - - 288 347 # 383 332 394 417 399 481 730 784 618 178 547 N/S 
Total - - - - 1764 2006 # 2161 1695 2130 2456 1975 2153 2934 2933 2171 1783 2253 N/S 
DDD/1000 PD, defined daily dose per 1000 patient-days; N/S, not significant; MRSA, methicillin-resistant Staphylococcus aureus; * Linear Regression: (p ≤ 0.05); 
Arrows indicate ASP start date for individual hospitals; # We were unable to calculate usage data for this quarter. 
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3.3. Antimicrobial Use 
No hospital had a statistically significant change in total antimicrobial usage between their ASP 
start date and June 2015 (Table 5). Quinolone use decreased 57.4% in hospital B (p = 0.001), 65.9% in 
hospital D (p < 0.001), and 67.3% in hospital E (p < 0.001). Hospitals B, D, and E also had statistically 
significant decreases in anti-pseudomonal prescribing. No hospital had a statistically significant 
change in anti-MRSA prescribing rates. There were significant increases in cephalosporin use in 
hospitals A, D and E. Macrolide use decreased in hospitals C and D and increased in hospital E. 
3.4. Antibiotic Susceptibility Profile 
Only hospital D had enough isolates for statistical analysis. P. aeruginosa susceptibility was 
examined because this organism is a common nosocomial pathogen. Between 2011 and 2015, 
susceptibility of P. aeruginosa improved to ciprofloxacin (38% to 76%, p = 0.13), piperacillin-tazobactam 
(66% to 100%, p = 0.05), and meropenem (60% to 95%, p = 0.06) at hospital D (Table 6). In the same 
time period, E. coli susceptibility to ciprofloxacin improved from 38% in 2011 to 54% by 2015  
(p = 0.19) (Table 6). There were no significant changes in rates of MRSA or Clostridium difficile 
infections at any of the facilities over the study period (data not shown). 
Table 6. Susceptibility rates for selected antimicrobials and organisms at hospital D by year. 
Antimicrobial 2011 2012 2013 2014 2015 p-Value 
E. coli 
Ciprofloxacin 16/51 (38%) 28/56 (50%) 19/55 (34%) 26/44 (59%) 23/42 (54%) 0.19 
P. aeruginosa 
Ciprofloxacin 12/31 (38%) 8/14 (57%) 23/28 (82%) 20/30 (66%) 20/26 (76%) 0.13 
Piperacillin/tazobactam 20/30 (66%) 21/24 (84%) 20/27 (74%) 27/30 (90%) 23/23 (100%) 0.05 
Meropenem 18/30 (60%) 21/24 (84%) 26/28 (92%) 28/30 (93%) 20/21 (95%) 0.06 
The numerator represents the number of organisms that were susceptible to the given antibiotic and the 
denominator is the total number of organisms tested. The number in parentheses is the percentage of the total 
number that were susceptible to the given antibiotic. 
4. Discussion 
In 2007, the IDSA and the Society for Healthcare Epidemiology of America (SHEA) released guidelines 
for developing institutional programs to better antimicrobial stewardship through use of the EMR [9]. 
VH has demonstrated long-term beneficial effects of an ASP and has used the EMR as a means of 
optimizing antimicrobial use [6,8]. This study is unique in that we can find no record of any hospital 
system using their EMR to remotely practice antimicrobial stewardship at community hospitals. 
Following expansion of the ASP to the community hospitals, 40%–63% of charts reviewed resulted 
in a recommendation being made with an 81%–95% physician acceptance rate. None of these 
recommendations occurred before the ASP was extended remotely to the community hospitals.  
This method provides an option for antimicrobial stewardship for smaller community hospitals and 
shows that physicians are willing to accept ASPs remotely. 
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The most commonly accepted intervention noted is drug discontinuation. This was associated with 
an average antimicrobial drug cost savings of $20,860.25 per hospital for the 4 largest hospitals over 
an 18 month period from January 2014 through June 2015. Again, this does not take into account 
additional cost savings that occur when adverse events are avoided, drugs are changed IV to PO, 
patient outcomes are optimized, and antimicrobial resistance is avoided. 
One of the main targets with each remote ASP was the reduction of quinolone use due to its 
increased risk for both Clostridium difficile infections (CDI) and MRSA infections [10,11]. Overall, 
we saw statistically significant decreases in quinolone use at hospitals B, D and E but did not see 
significant changes at hospitals A, C or F. This decrease in quinolone use may be a driving factor for 
the decrease in anti-pseudomonal drug usage as well. Two possible reasons why hospitals A and C did 
not experience decreases in quinolone use could be due to the fact that their quinolone use was 
considerably lower at the beginning of ASP implementation and because the ASP is newer at both of 
these hospitals.  
Some hospitals did see an increase in cephalosporin use. This may be a result of implementation of 
a dose optimization protocol that attempted to maximize pharmacokinetic and pharmacodynamic 
properties for certain pathogens and patient populations. For example, all surgical cefazolin dosing was 
increased from 1 g to 2 g, empiric cefepime dosing for hospital acquired infections was increased from 
1 g to 2 g every 12 h to 2 g every 8 h given by extended infusion, and ceftriaxone dosing was increased 
from 1 g to 2 g based on type of infection and patient specific parameters. While macrolide usage 
varied based on hospital, periodic analysis showed that most use of azithromycin is driven by the 
emergency department in the form of empiric sexually transmitted disease treatment or first dose for 
those not admitted to the hospital. 
One important note to make is related to total antimicrobial use at each hospital. Overall, there was 
not a statistically significant decrease in total antimicrobial use at any of the community hospitals.  
The ASP does not review patients in the emergency department, those who come to the hospital daily 
for infusions, or those who are on antibiotics for less than the 24 h period it takes to flag on the report. 
However, all of this antimicrobial usage is included within the total usage reported. In addition, total usage 
includes antimicrobials that are not on the controlled list and that would never flag for ASP review. 
The goal of ASPs is not only to reduce unnecessary use of antimicrobials, but also to improve 
resistance profiles. Because isolate numbers at each hospital were small, only hospital D’s isolate pool 
was large enough to analyze. There were improvements in antibiotic susceptibilities of P. aeruginosa 
to ciprofloxacin, piperacillin/tazobactam, and carbapenems over the four year time period. 
Establishing a remote ASP is not without challenges. There can be variation in local resources 
including diagnostics and formulary. While the VH formulary is now standardized, there is still 
variation in what drugs are stocked by each pharmacy and there are currently no formulary restrictions 
at the community hospitals. Determining how to identify patients can also be a challenge and may have 
to be modified over time. Distinguishing cases that need stewardship assistance vs. a formal infectious 
diseases consult can also be a challenge. 
Being a successful remote ASP does not stop with patient chart review. Continuing to develop 
relationships with the local staff (physicians, pharmacists, microbiology staff, and infection control 
practitioners) at the community hospitals is critical to improving patient care, as we view this as a team 
effort towards antimicrobial stewardship. The ASP pharmacists attempt to visit each community 
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hospital on a yearly basis in order to provide some face-to-face interaction, conduct educational 
opportunities desired by the pharmacy or physician staff, share results of the program, and gather 
feedback. This process also allows formal ASP introduction to any new or temporary staff. It is 
common for acceptance rates of new physicians to be low until they become comfortable with the 
advantages of the program. In addition to daily chart review, the ASP has been responsible for tasks 
including, but not limited to, helping manage antimicrobial shortages and formulary, creating order 
sets, answering questions for the local wound care centers, and distributing a guide book that is 
updated yearly and includes key information about managing infectious diseases. 
There are several limitations to this study. First, this study is based on aggregate data; the impact of 
the duration of antimicrobial use for an individual patient cannot be determined. Second, this dataset 
cannot correct for seasonal variation. Each ASP was implemented at a different time, with the oldest 
program running for four years and the youngest running for only one year. Because of these 
limitations, there were currently not enough data points to properly analyze antimicrobial patterns over 
the course of a year. Third, because of the small hospital sizes and small number of bacterial isolates, 
there was limited data regarding improvements in hospital antibiograms. 
5. Conclusions 
Remote ASPs utilizing the EMR provide an excellent alternative to the creation of new ASPs at 
small community hospitals with limited resources. Our data show that antimicrobial recommendations 
can be made and accepted at community hospitals at high percentages. Our data also show that we can 
potentially alter prescribing habits, save money, and change susceptibility patterns at community 
hospitals remotely as well. Overall, we have demonstrated successful implementation of a remote ASP 
through use of the EMR at small community hospitals. 
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